RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Hits Expectations

RenovoRx (NASDAQ:RNXT) posted its quarterly earnings data on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08), FiscalAI reports. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.42 million. RenovoRx had a negative net margin of 1,196.66% and a negative return on equity of 122.19%. During the same period in the previous year, the firm posted ($0.40) EPS.

Here are the key takeaways from RenovoRx’s conference call:

• RenovoRx achieved initial commercial traction with $1.1M in 2025 revenue, reported Q4 revenue of $238k, has 12 active U.S. centers (33-center near‑term pipeline) and is targeting ~36 active sites by year‑end 2026 with company guidance that 2026 revenue should be roughly $3M–$4M.
• The company strengthened its balance sheet with an oversubscribed private placement closing on March 23, 2026 that raised ~$10M gross, supplementing ~$7M cash at year‑end 2025 to fund commercial scale‑up and TIGeR‑PaC completion.
• The Phase III TIGeR‑PaC trial is nearing its enrollment target (104 of 114 randomized as of March 24, 2026) with 72 of 86 events observed and final data expected in 2027, representing a material clinical catalyst if positive.
• Near‑term revenue remains lumpy and scale‑constrained (quarterly results swing based on a small number of active centers and timing of first patient treatments), while R&D and SG&A run rates and the need to convert trial sites to commercial use pose execution and dilution risks if commercial adoption is slower than planned.

RenovoRx Trading Down 4.7%

Shares of NASDAQ:RNXT traded down $0.05 during trading on Tuesday, reaching $1.02. 447,377 shares of the company traded hands, compared to its average volume of 337,131. The firm has a market capitalization of $37.38 million, a price-to-earnings ratio of -2.84 and a beta of 1.34. RenovoRx has a 52-week low of $0.70 and a 52-week high of $1.45. The business’s fifty day moving average is $0.95 and its 200-day moving average is $1.01.

Analyst Ratings Changes

RNXT has been the subject of a number of research reports. Ascendiant Capital Markets upped their price objective on RenovoRx from $12.50 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of RenovoRx in a report on Monday, December 29th. JonesTrading raised RenovoRx to a “strong-buy” rating in a research note on Thursday, January 29th. Finally, Wall Street Zen upgraded shares of RenovoRx from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Institutional Investors Weigh In On RenovoRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its position in RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after buying an additional 18,525 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in shares of RenovoRx in the second quarter valued at about $98,000. Citadel Advisors LLC bought a new position in shares of RenovoRx during the third quarter valued at about $154,000. Wealthspire Advisors LLC bought a new position in shares of RenovoRx during the fourth quarter valued at about $212,000. Finally, Geode Capital Management LLC boosted its holdings in shares of RenovoRx by 9.9% during the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after purchasing an additional 31,730 shares during the period. 3.10% of the stock is currently owned by institutional investors.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.